Provincial Health Services Authority

Systemic Therapy Update

Volume 23 Issue 8
August 2020

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

Revised Programs: Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer (GUPCABA) | Biosimilar Rituximab

Provincial Systemic Therapy Program

***Revised Policy*:** Oncology Biosimilars Utilization [III-190]

Drug Shortages

New*:** Chlorambucil | ***Updated: Ranitidine Injection | ***Resolved:*** Alemtuzumab, Hydroxyurea

Cancer Drug Manual©

***New*:** Belantamab mafodotin, Trifluridine-tipiracil | ***Revised*:** Apalutamide, Atezolizumab, Avelumab, Cemiplimab, Crizotinib, Durvalumab, Ipilimumab, Lenvatinib, Nivolumab, Octreotide, Pembrolizumab, Rituximab | ***Retired*:** Olaratumab

Drug Update

Patient Assistance Programs

Benefit Drug List

Revised Protocols: **GI:** GIYTT | **GU:** GUAVNIV, GUAVNIV4, GUAXIT, GUCABO, GUPAZO, GUPCABA, GUSORAF, GUSUNI

NEW Protocols, PPPOs and Patient Handouts

GI: UGILEN | **GU:** GUPCABA

REVISED Protocols, PPPOs and Patient Handouts

CN: CNTEMOZ | **GI:** GIFUC, GIFUPART, GIPE, GIYTT | **GO:** GOOVFPLDC, GOOVPLDC | **GU:** GUAVNIV, GUAVNIV4, GUAXIT, GUCABO, GUFUPRT, GUNAJPG, UGUPAPA, GUPAZO, GUPCABA, UGUPENZ, GUSCPE, GUSORAF, GUSUNI | **HN:** HNNLAPRT | **LU:** LULAPERT, LUOTPE, LUOTPERT, LUPUPE, LUSCPE, LUSCPI | **LY:** LYABVD, LYBENDR, LYCHLRR, LYCHOPR, LYCHOPRMTX, LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFBR, LYCLLFLUDR, LYCODOXMR, LYCVPR, LYFCR, LYFLUDR, LYGDPR, LYIDELAR, LYIVACR, LYMFBEX, LYRICE, LYRITUX, LYRITZ, LYRMTN, LYVENETOR | **MY:** UMYBORPRE, UMYBORREL, UMYCARDEX, UMYCARLD, UMYLDF, UMYLDREL, MYMPBOR, UMYPOMDEX | **SA:** SAAJAP, SAAVAP | **SM:** SMAVTMZ, SMDTIC, SMIMI, SMMCCPE, SMPDT

Resources and Contact Information

Editor's Choice

Revised Programs

Effective 01 August 2020, the BC Cancer Provincial Systemic Therapy Program has revised the eligibility for the following treatment program. The full details of this program can be found on the BC Cancer website in the Chemotherapy Protocols section.

Genitourinary

Cabazitaxel for Metastatic Castrate-Resistant Prostate Cancer (GUPCABA) — Cabazitaxel is now approved as a later-line option in the sequencing of treatments for patients with metastatic castrate-resistant prostate cancer (mCRPC). Previously, only one of cabazitaxel or an androgen receptor axis-targeted (ARAT) agent (i.e., abiraterone or enzalutamide) was available for patients progressing on docetaxel, but not their sequential use. Moving forward, patients who have progressed on prior docetaxel-containing chemotherapy and within 12 months on abiraterone (UGUPABI) or enzalutamide (UGUPENZ) are eligible for cabazitaxel. Cabazitaxel is administered intravenously once every three weeks, together with daily prednisone. Androgen ablative therapy (i.e., LHRH agonist or LHRH antagonist) should be continued to maintain castrate testosterone levels in patients without orchiectomy. A BC Cancer Compassionate Access Program (CAP) approval is no longer required for cabazitaxel therapy.

Approval for the use of cabazitaxel is based on the results of the phase III CARD trial in patients with mCRPC that progressed after at least three cycles of docetaxel and within 12 months on an ARAT agent.[1]

Cabazitaxel (plus prednisone and filgrastim) was compared to the alternative ARAT agent (enzalutamide if abiraterone previously given, or vice versa). All patients without orchiectomy were maintained on an LHRH agonist or LHRH antagonist. The trial demonstrated improved median imaging-based progression-free survival (PFS), median overall survival (mOS) and PSA response in the cabazitaxel arm (median imaging-based PFS: 8.0 months vs. 3.7 months [HR 0.54, 95% CI 0.40-0.73]; mOS: 13.6 months vs. 11.0 months [HR 0.64, 95% CI 0.46-0.89]). Common grade 3 or higher adverse effects with cabazitaxel included neutropenia (44.7%), leukopenia (32.0%) and anemia (8.0%); those with an ARAT agent included renal disorders (8.1%), infection (7.3%) and musculoskeletal pain (5.6%). Adverse events leading to treatment discontinuation occurred more frequently with cabazitaxel than with ARAT therapy (19.8% vs. 8.9%).

References

1. De Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. *N Engl J Med* 2019;381:2506-2518. https://doi.org/10.1056/NEJMoa1911206

Biosimilar Rituximab Available

Effective 01 August 2020, the BC Cancer Provincial Systemic Therapy Program is implementing the use of biosimilar rituximab for rituximab given intravenously in BC Cancer treatment protocols. The rituximab biosimilars, RIXIMYO® and RUXIENCE®, are now eligible for reimbursement by BC Cancer. BC Cancer regional centres will stock RIXIMYO® as the designated biosimilar, in addition to the reference biologic product, RITUXAN®. Note that there is no change to the indication or use of subcutaneous rituximab and that the reference biologic formulation will continue to be used (RITUXAN SC®).

The following outlines key funding details:

- Patients starting on intravenous rituximab **on or after 01 August 2020** will be funded for biosimilar rituximab only. Requests for the use of the reference biologic, RITUXAN®, on or after 01 August will require submission through the BC Cancer Compassionate Access Program (CAP).
- Patients who started a treatment protocol with the intravenous reference biologic, RITUXAN®, **prior to 01 August 2020** and did not meet the clinical criteria to receive subcutaneous rituximab, may continue to receive RITUXAN® for the duration of the treatment protocol or until they are suitable to receive subcutaneous rituximab. Patients who are subsequently switched to or started on another rituximab-containing protocol on or after 01 August 2020 will be funded for biosimilar rituximab only (e.g., switched from LYCHOPR to LYGDPR; or started on LYRMTN after a prior rituximab protocol).
- Clinicians may choose to switch patients currently receiving the intravenous reference biologic to the biosimilar, after discussion with the patient.

The following highlights updates to BC Cancer documents:

- A **Pharmacy Selection Box** has been added to rituximab-containing **PPPOs**:

Pharmacy to select rituximab IV brand as per Provincial Systemic Therapy Policy III-190

Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date
rituximab		

- **Lymphoma PPPOs** – Affected PPPOs are noted in the *Revised Protocols, PPPOs and Patient Handouts* table at the end of the newsletter.
- **Rituximab Monograph**, **Patient Handout** and **Chemotherapy Preparation and Stability Chart** – Revisions are specified in the *Cancer Drug Manual* section below.
- **Oncology Biosimilars Utilization Policy [III-190]** – Updates are noted in the *Provincial Systemic Therapy Program* announcement below.

Provincial Systemic Therapy Program

Revised Policy: Oncology Biosimilars Utilization [III-190]

The BC Cancer Provincial Systemic Therapy Program has updated **Policy III-190 – Oncology Biosimilars Utilization** to include biosimilar rituximab. Information about the BC Cancer implementation of biosimilar rituximab is found in *Editor's Choice*. All Systemic Therapy policies can be found on the Shared Health Organizations Portal (SHOP) BC Cancer page.

Drug Shortages

The following are updates of drug supply shortages in BC. Full details about new, updated or resolved drug shortages, including recommended treatment alternatives, can be found in the *Briefing Notes* and email communications previously circulated to BC Cancer and the Community Oncology Network (CON).

New

Chlorambucil

(Adapted from BC Cancer Briefing Note 16July2020)

There is a potential shortage of chlorambucil 2 mg tablets, with limited quantities remaining at BC Cancer regional centres and Community Oncology Network (CON) sites. The estimated release date for additional supply is the end of October 2020. Supplies are being monitored and conservation strategies may be implemented if necessary.

Chlorambucil is funded by BC Cancer for the treatment of patients with low-grade lymphomas and chronic lymphocytic leukemia (LYCHLOR), for the palliative treatment of lymphoma (LYPALL), in combination with rituximab for indolent B-cell lymphomas (LYCHLRR) and chronic lymphocytic leukemia (LYCLLCHLR) and in combination with obinutuzumab for previously untreated chronic lymphocytic leukemia (LYOBCHLOR).

Recommended treatment alternatives for these indications include:

CURRENT TREATMENT	RECOMMENDED TREATMENT ALTERNATIVES
Chlorambucil alone	
LYCHLOR	Cyclophosphamide (dosing follows LYCYCLO or LYPALL)
LYPALL	Switch to LYPALL cyclophosphamide option
Chlorambucil with rituximab	
LYCHLRR	Reserve chlorambucil supply for combination therapy with rituximab
LYCLLCHLR	Reserve chlorambucil supply for combination therapy with rituximab
Chlorambucil with obinutuzumab	
LYOBCHLOR	Reserve chlorambucil supply for combination therapy with obinutuzumab

Drug Shortages

Updated

Ranitidine Injection

(Adapted from BC Cancer Briefing Note Update 27July2020)

A recall of several lot numbers of 2 mL and 50 mL parenteral ranitidine was announced on 24 July 2020 by Sandoz Canada, the only parenteral ranitidine manufacturer in Canada. The affected lot numbers may have particulate matter present in the vials. The manufacturer has asked that all supplies of affected lot numbers be quarantined immediately.

BC Cancer regional centres and Community Oncology Network (CON) sites may have no or limited supply of unaffected lot numbers. Please refer to the full briefing note for therapeutic alternatives to parenteral ranitidine. Oral ranitidine products not affected by the N-nitrodimethylamine (NDMA) recall continue to be available.

Resolved

Alemtuzumab

(Adapted from BC Cancer email communication 03Jul2020)

Alemtuzumab supplies are now available.

Hydroxyurea

(Adapted from BC Cancer email communication 03Jul2020)

Hydroxyurea supplies are expected to be available on an ongoing basis and the shortage is now considered resolved. BC Cancer pharmacies have moved back to dispensing a 3-month supply.

Cancer Drug Manual©

All BC Cancer Drug Manual© documents can be accessed from the Cancer Drug Manual© home page on the BC Cancer website.

New Documents

Note that the following drugs are NOT BC Cancer Benefit Drugs and require application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monographs and Patient Handout are made available for reference only.

The **Belantamab mafodotin Interim Monograph** has been developed. Belantamab mafodotin is an antibody-drug conjugate that binds specifically to the B-cell maturation antigen (BCMA). The monoclonal antibody component (belantamab) is linked to the active cytotoxic drug (monomethyl auristatin F). The usual dose in the treatment of multiple myeloma is 2.5 mg/kg IV given on day 1 of a three-week cycle.

Highlights from this document include:

- corneal events (e.g., keratopathy, blurry vision, dry eye, photophobia) are the most common adverse reactions; avoid contact lens use for duration of treatment with belantamab mafodotin
- prophylactic antiviral therapy is recommended for hepatitis B core antibody (anti-HBc)-positive patients
- premedication may be required to manage infusion-related reactions
- myelosuppression, including thrombocytopenia, neutropenia, anemia, is reported

Belantamab mafodotin has been added to the **Chemotherapy Preparation and Stability Chart** and has been evaluated for the **BC Cancer Hazardous Drug List.**

The **Trifluridine-tipiracil Interim Monograph and Patient Handout** have been developed with expert review provided by Dr. Howard Lim (medical oncologist) of the BC Cancer Gastrointestinal Tumour Group. Trifluridine, the active cytotoxic component of trifluridine-tipiracil, is a thymidine-based antimetabolite. The tipiracil component allows for the maintenance of adequate levels of trifluridine by preventing its rapid degradation. Trifluridine-tipiracil is used in the treatment of metastatic colorectal cancer, gastric cancer and adenocarcinoma of the gastroesophageal junction. The usual dose is 35 mg/m^2 given orally twice daily with food at the morning and evening meals, on days 1-5 and days 8-12 of each 28-day cycle. Dosing is based on the trifluridine component.

Highlights from these documents include:

- myelosuppression is common and serious infections have been reported
- fatigue and appetite decrease are frequently reported

Trifluridine-tipiracil has been added to the **Auxiliary Label List** and has been evaluated for the **BC Cancer Hazardous Drug List**.

Cancer Drug Manual©

Revised Documents

Highlights of key changes are listed below:

Apalutamide Monograph

Supply and Storage: updated best-use dates for tablets in *Additional Information*

Crizotinib Monograph

Side Effects: added recommended management for sudden severe vision loss
Dosage Guidelines: updated hepatic dosing

Lenvatinib Monograph

Uses: updated with Health Canada approved indications
Cautions: added warning regarding impaired thyroid suppression and suggested monitoring
Side Effects: added hypothyroidism to table
Supply and Storage: updated blister packaging information with new dosing regimens in *Additional Information*
Dosage Guidelines: added new dosing regimens; updated hepatic and renal dosing

Octreotide Monograph

Reviewed and updated the following sections: *Mechanism, Pharmacokinetics, Cautions, Interactions, Supply and Storage, Parenteral Administration table* and *Dosage Guidelines*
Side Effects: added `loss of symptomatic control` to paragraph

Rituximab Monograph, Patient Handout and **Chemotherapy Preparation and Stability Chart**

Common Trade Names: updated with new biosimilar brand names, deleted European brand name
Cautions: clarified information pertaining to RITUXAN® SC with respect to new biosimilar brands
Supply and Storage: added information pertaining to new biosimilar formulations
Patient Handout: updated *Other names* with new biosimilar brand names
Chemotherapy Preparation and Stability Chart: added new biosimilar formulations; updated originator formulations with brand name

The following **Patient Handouts** have been updated to include information about immunotherapy in both the bullets and Side Effects table preamble:

Atezolizumab
Avelumab
Cemiplimab
Durvalumab
Ipilimumab
Nivolumab
Pembrolizumab

Retired Documents

The **Olaratumab Interim Monograph** has been retired. **Olaratumab** has been deleted from the **Chemotherapy Preparation and Stability Chart** and **Hazardous Drug List**.

Drug Update

Manufacturer Patient Assistance Programs

The listing of patient assistance programs offered by pharmaceutical manufacturers has been updated and can be accessed on the BC Cancer website under Health Professionals > Systemic Therapy > Reimbursement & Forms.

Benefit Drug List

Revised Programs

Effective 01 August 2020, the following treatment programs no longer require Compassionate Access Program (CAP) approval and have been transferred to Class I status on the BC Cancer Benefit Drug List:

Protocol Title	Protocol Code	Benefit Status
Yttrium-90 for Transarterial Radioembolisation (TARE)	**GIYTT**	Class I *(Previously Restricted)*
Treatment of Metastatic or Advanced Renal Cell Carcinoma using **Nivolumab**	**GUAVNIV**	Class I *(Previously Restricted)*
Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly **Nivolumab**	**GUAVNIV4**	Class I *(Previously Restricted)*
Therapy for Metastatic Renal Cell Carcinoma using **Axitinib**	**GUAXIT**	Class I *(Previously Restricted)*
Therapy for Metastatic Renal Cell Carcinoma using **Cabozantinib**	**GUCABO**	Class I *(Previously Restricted)*
Palliative Therapy for Renal Cell Carcinoma using **Pazopanib**	**GUPAZO**	Class I *(Previously Restricted)*
Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using **Cabazitaxel** and **Prednisone**	**GUPCABA**	Class I *(Previously Restricted, expanded Eligibility)*
Palliative Therapy for Renal Cell Carcinoma using **Sorafenib**	**GUSORAF**	Class I *(Previously Restricted)*
Palliative Therapy for Renal Cell Carcinoma using **Sunitinib**	**GUSUNI**	Class I *(Previously Restricted)*

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts *(new documents checked ☑)*

Code	Protocol Title	Protocol	PPPO	Handout
UGILEN	First-Line Therapy of Advanced Hepatocellular Carcinoma using Lenvatinib	☐	☐	☑
GUPCABA	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Cabazitaxel and Prednisone	☐	☐	☑

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Code	Protocol Title	Protocol	PPPO	Handout
CN | Neuro-Oncology				
CNTEMOZ	Therapy for Malignant Brain Tumours using Temozolomide	*Eligibility revised*	-----	-----
GI | Gastrointestinal				
GIFUC	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder Carcinoma and Cholangiocarcinoma) and Metastatic Anal Cancer using Infusional Fluorouracil and Cisplatin	-----	*Formatted with TALLman lettering*	-----
GIFUPART	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Infusional Fluorouracil and Radiation Therapy	-----	*Formatted with TALLman lettering and Tests clarified*	-----
GIPE	Palliative Therapy of Neuroendocrine Tumours using Cisplatin and Etoposide	-----	*Cisplatin infusion time clarified*	-----
~~U~~GIYTT	Yttrium-90 for Transarterial Radioembolisation (TARE)	*Protocol Code (**U** removed) and Eligibility revised; Contact Physician updated*	-----	-----
GO | Gynecology				
GOOVFPLDC	First-Line Treatment of Epithelial Ovarian Cancer using Doxorubicin Pegylated Liposomal (CAELYX®) and Carboplatin	*Tests updated (AST replaced by ALT)*	*Priming solution for IV line clarified and AST removed*	-----

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*				
Code	**Protocol Title**	**Protocol**	**PPPO**	**Handout**
GOOVPLDC	Treatment of Epithelial Ovarian Cancer Relapsing after Primary Treatment using Doxorubicin Pegylated Liposomal (CAELYX®) and Carboplatin	*Tests updated (AST replaced by ALT)*	*Priming solution for IV line clarified and AST removed*	-----
GU | Genitourinary				
~~U~~GUAVNIV	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	*Protocol Code revised (**U** removed)*
~~U~~GUAVNIV4	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	*Protocol Code revised (**U** removed)*
~~U~~GUAXIT	Therapy for Metastatic Renal Cell Carcinoma using Axitinib	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	-----
~~U~~GUCABO	Therapy for Metastatic Renal Cell Carcinoma using Cabozantinib	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	-----
GUFUPRT	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System using Fluorouracil and Cisplatin with Radiation	-----	*Formatted with TALLman lettering and AST deleted*	-----
GUNAJPG	Neoadjuvant Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	-----	*Formatted with TALLman lettering*	-----
UGUPAPA	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Apalutamide	*Eligibility and treatment algorithm updated*	-----	-----
~~U~~GUPAZO	Palliative Therapy for Renal Cell Carcinoma using Pazopanib	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	*Protocol Code revised (**U** removed)*

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*				
Code	**Protocol Title**	**Protocol**	**PPPO**	**Handout**
~~U~~**GUPCABA**	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Cabazitaxel and Prednisone	*Protocol Code (**U** removed) and Eligibility revised; Contact Physician updated; Alternate steroid dosing clarified; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed; Alternate steroid dosing clarified*	*Handout created*
UGUPENZ	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	*Eligibility and Contact Physician updated; Treatment algorithm added*	-----	-----
GUSCPE	Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
~~U~~**GUSORAF**	Palliative Therapy for Renal Cell Carcinoma using Sorafenib	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	*Protocol Code revised (**U** removed)*
~~U~~**GUSUNI**	Palliative Therapy for Renal Cell Carcinoma using Sunitinib	*Protocol Code (**U** removed) and Eligibility revised; Treatment algorithm added*	*CAP requirement and **U** in Protocol Code removed*	*Protocol Code revised (**U** removed)*
HN | Head and Neck				
HNNLAPRT	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation	-----	*Institutional name and logo updated; Formatted with TALLman lettering; Tests clarified*	-----
LU | Lung				
LULAPERT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
LUOTPE	Treatment of Thymoma with Cisplatin and Etoposide	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
LUOTPERT	Treatment of Thymoma using Cisplatin and Etoposide with Radiation Therapy	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with Cisplatin and Etoposide	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*				
Code	**Protocol Title**	**Protocol**	**PPPO**	**Handout**
LUSCPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Cisplatin and Etoposide	*Cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
LUSCPI	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan with or without Platinum	-----	*Formatted with TALLman lettering*	-----
LY | Lymphoma				
LYABVD	Treatment of Hodgkin's Disease with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine	*Cardiac monitoring threshold revised*	-----	-----
LYBENDR	Treatment of Non-Hodgkin Lymphoma with Bendamustine and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCHLRR	Treatment of Indolent B-Cell Lymphoma Chlorambucil and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCHOPR	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCHOPRMTX	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCLLBENDR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCLLCHLR	Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCLLCVPR	Treatment of Relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	*Rituximab timing clarified*	*Biosimilar Pharmacy Selection Box added*	-----
LYCLLFBR	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCLLFLUDR	Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYCODOXMR	Treatment of Burkitt's Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab	*Cyclophosphamide bag size revised*	*Cyclophosphamide bag size revised and Biosimilar Pharmacy Selection Box added*	-----
LYCVPR	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	-----	*Biosimilar Pharmacy Selection Box added*	-----

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*				
Code	**Protocol Title**	**Protocol**	**PPPO**	**Handout**
LYFCR	Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYFLUDR	Treatment of Relapsed Indolent Lymphoma with Fludarabine and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYGDPR	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYIDELAR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) using Idelalisib and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYIVACR	Treatment of Burkitt's Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYMFBEX	Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides/Sézary syndrome) with Bexarotene	*Eligibility clarified*	-----	-----
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYRITUX	Treatment of Lymphoma with Single-Agent Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYRITZ	Palliative Therapy For Lymphoma using Radioimmunotherapy: Rituximab-Priming for Ibritumomab ^{90}Y (ZEVALIN®)	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYRMTN	Maintenance Rituximab for Indolent Lymphoma	-----	*Biosimilar Pharmacy Selection Box added*	-----
LYVENETOR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Rituximab	-----	*Biosimilar Pharmacy Selection Box added*	-----
MY | Myeloma				
UMYBORPRE	Treatment of Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant	*Supportive medications revised*	-----	-----
UMYBORREL	Treatment of Relapsed Multiple Myeloma using Bortezomib, Dexamethasone with or without Cyclophosphamide	*Supportive medications revised*	-----	-----

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*				
Code	**Protocol Title**	**Protocol**	**PPPO**	**Handout**
UMYCARDEX	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone with or without Cyclophosphamide	*Cyclophosphamide dosing clarified and supportive medications revised*	-----	-----
UMYCARLD	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	*Supportive medications revised*	-----	-----
UMYLDF	Treatment of Previously Untreated Multiple Myeloma and Not-Eligible for Stem Cell Transplant using Lenalidomide with Low-Dose Dexamethasone	*Supportive medications revised*	-----	-----
UMYLDREL	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone	*Supportive medications revised*	-----	-----
MYMPBOR	Treatment of Multiple Myeloma using Melphalan, Prednisone and Weekly Bortezomib with the Option of Substituting Cyclophosphamide for Melphalan	*Supportive medications revised*	-----	-----
UMYPOMDEX	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	*Supportive medications revised*	-----	-----
SA | Sarcoma				
SAAJAP	Adjuvant Therapy for Osteosarcoma using Doxorubicin and Cisplatin	*Antiemetics updated (ondansetron)*	-----	-----
SAAVAP	Therapy of Advanced Osteosarcoma using Doxorubicin and Cisplatin	*Antiemetics updated (ondansetron)*	-----	-----
SM | Skin and Melanoma				
SMAVTMZ	Palliative Therapy for Malignant Melanoma with Brain Metastases using Temozolomide	-----	-----	*Institutional name and logo updated*
SMDTIC	Palliative Therapy for Metastatic Malignant Melanoma using High-Dose Dacarbazine	-----	-----	*Institutional name and logo updated*
SMIMI	Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma using Imiquimod	*Institutional name updated*	-----	-----
SMMCCPE	Treatment of Recurrent or Metastatic Merkel Cell Carcinoma (MCC) with Cisplatin and Etoposide	*Institutional name and Contact Physician updated; Tests and cisplatin infusion time clarified*	*Cisplatin infusion time clarified*	-----
SMPDT	Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy)	*Institutional name updated*	-----	-----

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor Pharmacy Oncology Certification Nurse Educators	604-877-6275 250-519-5500 x 693742 250-712-3900 x 686820 604-877-6000 x 672638	druginfo@bccancer.bc.ca nbadry@bccancer.bc.ca rxchemocert@bccancer.bc.ca nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Program	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mlin@bccancer.bc.ca BCCancerPPNAdmin@ehcnet.phsa.ca mlin@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board